Shares in Emerald Clinics Ltd (ASX: EMD) have surged nearly 30% in early trade following an announcement from the company. At the time of writing, the Emerald Clinics share price had risen 29.5% to currently trade at 7.9 cents.
What did Emerald Clinics announce?
Earlier today, Emerald Clinics released an announcement which highlighted record appointments in Australia, plans for international expansion and a proposed name change.
Despite the restrictions induced by COVID-19, Emerald Clinics reported a record 795 appointments in July. The company noted continued month-on-month growth in comparison to subdued demand in the majority of health services.
As a result, Emerald Clinics informed investors that the company is actively hiring clinicians in order to meet growing demand for its services. In addition, the company is expanding its remote monitoring capabilities and increasing its data insight platforms.
Emerald Clinics also announced that the company intends to change its name to Emyria Limited. According to the company, the proposed name change is consistent with its global ambitions and rebranding, the latter of which better communicates its scope of practice. The planned name change follows the company’s data collaboration with a United Kingdom partner.
What does Emerald Clinics do?
Emerald Clinics is network of specialist and referral only medical clinics. The company’s clinicians are trained specialists in the application of unregistered medicines, which include cannabinoid products.
The company also focuses on collecting and developing high quality, real-world evidence (RWE) data. Emerald’s RWE data platform aims to improve patient care, identify novel uses for existing therapies and explore the performance of certain medicines.
As a result, the data insights from Emerald’s RWE platforms can also be provided to pharmaceutical companies on a subscription payment model.
Emerald Clinics recently signed with Spectrum Biomedical, a UK-based subsidiary of the world’s largest cannabis company Canopy Growth Corp. Under the agreement, Emerald will design and deliver RWE focused on the safety and clinical outcomes of cannabis-based medicines produced by Spectrum.
Foolish takeaway
At the time of writing, the Emerald Clinics share price is trading nearly 30% higher at 7.9 cents. Shares in the company were up nearly 40% earlier today after hitting an intra-day high of 8.5 cents.
5 stocks under $5
We hear it over and over from investors, “I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I’d be sitting on a gold mine!” And it’s true.
And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!
*Extreme Opportunities returns as of June 5th 2020
More reading
- Alicanto share price exploding 20%, here’s why
- Why today is a great day to add to your ASX share portfolio
- These exciting ASX tech shares could be perfect buy and hold options
- Brokers name 3 ASX shares to buy right now
- ASX shares that could take a hit from New Zealand lockdowns
Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post Emerald Clinics share price soars 30% on new record appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/3iIEdd5
Leave a Reply